stockrowCharles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
Follow CRL
Alert me
Charles River Laboratories International, Inc. 10-Q filed Aug 5, 2026
Red flags
-
Inventory outpacing revenue
Inventory grew 23.9% while revenue grew -2.7% year over year
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 7, 2026: 25 added · 5 removed · 34 modified; 8 with only figures updated; 7 moved without change
-
Modified · Segment Reporting
Our RMS reportable segment includes the products and services offered within Research Models, Research Model Services, and Cell Solutions. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of our clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities as well as our own vivarium space, utilizing our Charles River Accelerator and Development Lab (CRADLTM) offerings, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models
; and. In May 2026, we sold the Cell Solutions business, reported in the RMS segment, whichprovidesprovided controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow as well as cells from disease state donors.